Document is current
Any future updates will be listed below
-
Authors
Satoh-Kanda, Yurie https://orcid.org/0000-0001-6484-2360
Nakayamada, Shingo
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05858645 at ClinicalTrials.govnct05556265 at ClinicalTrials.govDocuments that mention this clinical trial
Fine-tuning SLE treatment: the potential of selective TYK2 inhibition
https://doi.org/10.1136/rmdopen-2024-005072
nct04877990 at ClinicalTrials.govDocuments that mention this clinical trial
Fine-tuning SLE treatment: the potential of selective TYK2 inhibition
https://doi.org/10.1136/rmdopen-2024-005072
nct04857034 at ClinicalTrials.govDocuments that mention this clinical trial
Fine-tuning SLE treatment: the potential of selective TYK2 inhibition
https://doi.org/10.1136/rmdopen-2024-005072
nct03252587 at ClinicalTrials.govDocuments that mention this clinical trial
AB0609 DESIGN OF A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIAL OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2023-eular.1712
LP-180 Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosus
https://doi.org/10.1136/lupus-2023-kcr.255
Fine-tuning SLE treatment: the potential of selective TYK2 inhibition
https://doi.org/10.1136/rmdopen-2024-005072
nct03920267 at ClinicalTrials.govDocuments that mention this clinical trial
POS0341 DECONVOLUTION OF TRANSCRIPTOMICS CHANGES IN DEUCRAVACITINIB-TREATED SUBJECTS REVEALS NOVEL MECHANISTIC EFFECTS OF TYK2 INHIBITION IN LUPUS
https://doi.org/10.1136/annrheumdis-2024-eular.1880
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial
https://doi.org/10.1136/lupus-2025-001517
P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study
https://doi.org/10.1136/lupus-2024-el.217
S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
https://doi.org/10.1136/lupus-2022-elm2022.23
POS0543 KINETICS OF MUCOCUTANEOUS AND MUSCULOSKELETAL RESPONSES TO DEUCRAVACITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE PHASE 2 PAISLEY TRIAL
https://doi.org/10.1136/annrheumdis-2024-eular.1790
LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.5020a
OP0048 CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX (CLASI) ACHIEVEMENT AND SUSTAINED RESPONSE WITH DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2024-eular.584
POS0112 DEUCRAVACITINIB REDUCES INTERFERONS, B-CELL PATHWAYS, AND SEROLOGICAL BIOMARKERS OF SYSTEMIC LUPUS DISEASE ACTIVITY: PHARMACODYNAMIC ANALYSIS FROM THE PHASE 2 PAISLEY STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.1719
PT4:06 Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: results from the phase 2 PAISLEY SLE trial
https://doi.org/10.1136/lupus-2026-el.53
LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2023-kcr.257
AB0515 PHARMACOKINETICS, SELECTIVITY PROFILE, AND EXPOSURE-RESPONSE RELATIONSHIP FOR EFFICACY AND SAFETY IN A PHASE 2 STUDY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2023-eular.1714
Fine-tuning SLE treatment: the potential of selective TYK2 inhibition
https://doi.org/10.1136/rmdopen-2024-005072
LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study
https://doi.org/10.1136/lupus-2023-kcr.56
OP0099 LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) ACHIEVEMENT WITH DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2024-eular.583
O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus
https://doi.org/10.1136/lupus-2024-el.41
P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial
https://doi.org/10.1136/lupus-2024-el.219
POS0527 DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): EFFICACY BY BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN THE PHASE 2 PAISLEY TRIAL
https://doi.org/10.1136/annrheumdis-2024-eular.250
LO-015 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in a phase 2 trial in systemic lupus erythematosus (SLE): achievement of sustained SRI(4), BICLA, and dual responses over 48 weeks
https://doi.org/10.1136/lupus-2023-kcr.15
POS0542 EFFICACY OF DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS: A SUBANALYSIS OF THE PHASE 2 PAISLEY STUDY
https://doi.org/10.1136/annrheumdis-2024-eular.1522
LP-187 Abstract withdrawn
https://doi.org/10.1136/lupus-2023-kcr.262
5 Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY)
https://doi.org/10.1136/lupus-2019-lsm.5
AB1374 DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.245
nct05617677 at ClinicalTrials.govDocuments that mention this clinical trial
PT4:06 Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: results from the phase 2 PAISLEY SLE trial
https://doi.org/10.1136/lupus-2026-el.53
Fine-tuning SLE treatment: the potential of selective TYK2 inhibition
https://doi.org/10.1136/rmdopen-2024-005072
nct05620407 at ClinicalTrials.govDocuments that mention this clinical trial
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial
https://doi.org/10.1136/lupus-2025-001517
LP-179 Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus
https://doi.org/10.1136/lupus-2023-kcr.254
AB0609 DESIGN OF A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIAL OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2023-eular.1712
PT4:06 Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: results from the phase 2 PAISLEY SLE trial
https://doi.org/10.1136/lupus-2026-el.53
LP-180 Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosus
https://doi.org/10.1136/lupus-2023-kcr.255
Fine-tuning SLE treatment: the potential of selective TYK2 inhibition
https://doi.org/10.1136/rmdopen-2024-005072
AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2023-eular.3881
nct03252587 at ClinicalTrials.govDocuments that mention this clinical trial
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial
https://doi.org/10.1136/lupus-2025-001517
LP-179 Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus
https://doi.org/10.1136/lupus-2023-kcr.254
AB0609 DESIGN OF A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIAL OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2023-eular.1712
PT4:06 Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: results from the phase 2 PAISLEY SLE trial
https://doi.org/10.1136/lupus-2026-el.53
LP-180 Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosus
https://doi.org/10.1136/lupus-2023-kcr.255
Fine-tuning SLE treatment: the potential of selective TYK2 inhibition
https://doi.org/10.1136/rmdopen-2024-005072
AB0530 DESIGN OF 2 PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIALS OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2023-eular.3881
Documents that mention this clinical trial
POS0341 DECONVOLUTION OF TRANSCRIPTOMICS CHANGES IN DEUCRAVACITINIB-TREATED SUBJECTS REVEALS NOVEL MECHANISTIC EFFECTS OF TYK2 INHIBITION IN LUPUS
https://doi.org/10.1136/annrheumdis-2024-eular.1880
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial
https://doi.org/10.1136/lupus-2025-001517
P163 Efficacy of deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, in musculoskeletal manifestations of systemic lupus erythematosus: a subanalysis of the phase 2 PAISLEY study
https://doi.org/10.1136/lupus-2024-el.217
S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
https://doi.org/10.1136/lupus-2022-elm2022.23
POS0543 KINETICS OF MUCOCUTANEOUS AND MUSCULOSKELETAL RESPONSES TO DEUCRAVACITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE PHASE 2 PAISLEY TRIAL
https://doi.org/10.1136/annrheumdis-2024-eular.1790
LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
https://doi.org/10.1136/annrheumdis-2022-eular.5020a
OP0048 CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX (CLASI) ACHIEVEMENT AND SUSTAINED RESPONSE WITH DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2024-eular.584
POS0112 DEUCRAVACITINIB REDUCES INTERFERONS, B-CELL PATHWAYS, AND SEROLOGICAL BIOMARKERS OF SYSTEMIC LUPUS DISEASE ACTIVITY: PHARMACODYNAMIC ANALYSIS FROM THE PHASE 2 PAISLEY STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.1719
LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus
https://doi.org/10.1136/lupus-2023-kcr.257
PT4:06 Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: results from the phase 2 PAISLEY SLE trial
https://doi.org/10.1136/lupus-2026-el.53
AB0515 PHARMACOKINETICS, SELECTIVITY PROFILE, AND EXPOSURE-RESPONSE RELATIONSHIP FOR EFFICACY AND SAFETY IN A PHASE 2 STUDY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2023-eular.1714
Fine-tuning SLE treatment: the potential of selective TYK2 inhibition
https://doi.org/10.1136/rmdopen-2024-005072
LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study
https://doi.org/10.1136/lupus-2023-kcr.56
OP0099 LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) ACHIEVEMENT WITH DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN SYSTEMIC LUPUS ERYTHEMATOSUS
https://doi.org/10.1136/annrheumdis-2024-eular.583
O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI[4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor in the phase 2 PAISLEY trial in systemic lupus erythematosus
https://doi.org/10.1136/lupus-2024-el.41
P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial
https://doi.org/10.1136/lupus-2024-el.219
POS0527 DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): EFFICACY BY BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN THE PHASE 2 PAISLEY TRIAL
https://doi.org/10.1136/annrheumdis-2024-eular.250
LO-015 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in a phase 2 trial in systemic lupus erythematosus (SLE): achievement of sustained SRI(4), BICLA, and dual responses over 48 weeks
https://doi.org/10.1136/lupus-2023-kcr.15
POS0542 EFFICACY OF DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN MUSCULOSKELETAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS: A SUBANALYSIS OF THE PHASE 2 PAISLEY STUDY
https://doi.org/10.1136/annrheumdis-2024-eular.1522
LP-187 Abstract withdrawn
https://doi.org/10.1136/lupus-2023-kcr.262
5 Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY)
https://doi.org/10.1136/lupus-2019-lsm.5
AB1374 DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS
https://doi.org/10.1136/annrheumdis-2024-eular.245
- License Information
